All In Biotech

Drug Trial Radar · NCT07441174

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

A Multicenter, Open-Label, Phase Ib/II Clinical Trial of IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Feb 28, 2026

Primary completion

Feb 28, 2031

Study completion Feb 28, 2031

Sponsor

Lead sponsor
InxMed (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Ranok Therapuetics Co. Ltd.; InxMed (Shenzhen) Co.,Ltd.
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.

Conditions

  • Solid Tumor Cancer
  • PDAC

Interventions

  • IN10018 in combination with RNK08954Drug

    Based on existing clinical data, the RP2D of IN10018 as monotherapy and in combination with chemotherapy, targeted therapy, and immunotherapy is 100 mg QD. For RNK08954 as monotherapy, the Maximum Tolerated Dose (MTD) was not reached during the dose escalation of the Phase I study, and effective doses with observed tumor responses were 800 mg QD, 1000 mg QD, and 1200 mg QD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib:Recommended phase II dose (RP2D) of IN10018 in combination with RNK08954Time frame: Approximately 6 months
  2. Phase II: To evaluate the rate of Objective Response Rate (ORR) of IN10018 in combination with RNK08954 in subjects with KRASG12D mutation-positive locally advanced or metastatic solid tumors.Time frame: Approximately 5 years

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, He, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital of China Medical University

    Shengyang, Liaoning, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Not yet recruiting

  • Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310005

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.